GNG is developing its Biosimilar portfolio with National Biopharma Mission 

The company aims to develop its clone development capability for biosimilar molecule, currently its developing biosimilar inhibitor against TNF alpha

The company is also having some novel biological entity in pipeline for various target both including inflammation and infectious disease.

© 2018 by www.gng.asia